Cocrystal Pharma Stock Current Liabilities
| COCP Stock | USD 1.88 0.10 5.05% |
Cocrystal Pharma fundamentals help investors to digest information that contributes to Cocrystal Pharma's financial success or failures. It also enables traders to predict the movement of Cocrystal Stock. The fundamental analysis module provides a way to measure Cocrystal Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cocrystal Pharma stock.
As of 12/11/2024, Non Current Liabilities Other is likely to grow to about 366.4 K, while Total Current Liabilities is likely to drop slightly above 2.7 M. Cocrystal | Current Liabilities |
Cocrystal Pharma Company Current Liabilities Analysis
Cocrystal Pharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Cocrystal Pharma Current Liabilities | 3.15 M |
Most of Cocrystal Pharma's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cocrystal Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cocrystal Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Cocrystal Pharma is extremely important. It helps to project a fair market value of Cocrystal Stock properly, considering its historical fundamentals such as Current Liabilities. Since Cocrystal Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cocrystal Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cocrystal Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Cocrystal Current Liabilities Historical Pattern
Today, most investors in Cocrystal Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cocrystal Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cocrystal Pharma current liabilities as a starting point in their analysis.
Cocrystal Pharma Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Cocrystal Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Cocrystal Pharma has a Current Liabilities of 3.15 M. This is 99.82% lower than that of the Pharmaceuticals sector and 99.42% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.96% higher than that of the company.
Cocrystal Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cocrystal Pharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics of similar companies.Cocrystal Pharma is currently under evaluation in current liabilities category among its peers.
Cocrystal Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 8.19 M | ||||
| Shares Outstanding | 10.17 M | ||||
| Shares Owned By Insiders | 31.85 % | ||||
| Shares Owned By Institutions | 6.94 % | ||||
| Number Of Shares Shorted | 8.01 K | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (8.79 M) | ||||
| EBITDA | (19.37 M) | ||||
| Net Income | (17.98 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (14.67 M) | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 19.94 M | ||||
| Total Asset | 31.26 M | ||||
| Retained Earnings | (315.91 M) | ||||
| Working Capital | 25.83 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
| Net Asset | 31.26 M |
About Cocrystal Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cocrystal Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Cocrystal Stock
Moving against Cocrystal Stock
| 0.64 | AMGN | Amgen Inc | PairCorr |
| 0.63 | ABBV | AbbVie Inc | PairCorr |
| 0.6 | TTOO | T2 Biosystms | PairCorr |
| 0.58 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.57 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.